Reimbursement of innovative pharmaceuticals in English and Spanish hospitals—The example of isavuconazole

Jeck, Julia, Wingen-Heimann, Sebastian M., Thielscher, Christian, Kron, Anna, Bonn, Jennifer, Jakobs, Florian, Grau, Santiago, Enoch, David A., Micallef, Christianne ORCID: https://orcid.org/0000-0002-4513-8199, Cornely, Oliver A. and Kron, Florian (2021) Reimbursement of innovative pharmaceuticals in English and Spanish hospitals—The example of isavuconazole. Mycoses, 64 (10). pp. 1213-1222. ISSN 0933-7407

[thumbnail of Mycoses - 2021 - Jeck - Reimbursement of innovative pharmaceuticals in English and Spanish hospitals The example of]
Preview
PDF (Mycoses - 2021 - Jeck - Reimbursement of innovative pharmaceuticals in English and Spanish hospitals The example of) - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview

Abstract

Background: Kron et al (Mycoses, 64, 2021, 86) found cost savings for the use of the innovative pharmaceutical isavuconazole in the inpatient setting in Germany (Bismarck-based healthcare system). Little is known about the reimbursement of innovative pharmaceuticals in the inpatient setting of Beveridge-based healthcare systems. Objectives: The aim of this study was to evaluate the market access process and reimbursement of isavuconazole, exemplary for innovative pharmaceuticals, in England and Spain. Patients/Methods: Market access processes of both countries were described. Focussing on typical patient clusters for isavuconazole treatment, reimbursement data regarding inpatients with (i) allogeneic haematopoietic stem cell transplantation or (ii) acute myeloid leukaemia was considered. Data were publicly available and of high topicality (England 2020/2021, Spain 2018). Discounting and a currency conversion to Euro were applied. Results: This study showed that market access processes of both countries are broadly similar. Further, full reimbursement of isavuconazole as an innovative pharmaceutical may lead to reduction in resource utilisation. Without medication costs, isavuconazole can thus result in cost savings for both patient clusters due to a reduction in length of stay. Conclusions: Expenses for innovative pharmaceuticals may be balanced or even lead to cost savings due to a reduction in length of stay. The latter contributes to a greater patient benefit. For both healthcare system, the analyses highlighted drugs’ cost-effectiveness and assessing its added value into reimbursement decisions is highly relevant.

Item Type: Article
Additional Information: Funding Information: This study was funded by Pfizer Inc Julia Jeck, Sebastian M. Wingen‐Heimann, Anna Kron, Jennifer Bonn, Florian Jakobs and Florian Kron are employees of VITIS Healthcare Group, who were paid consultants to Pfizer in connection with the development of this manuscript.
Uncontrolled Keywords: antifungal treatment,beveridge healthcare system,invasive aspergillosis,invasive fungal diseases,invasive mucormycosis,isavuconazole,dermatology,infectious diseases,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700/2708
Faculty \ School: Faculty of Science > School of Pharmacy
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 18 Aug 2022 09:30
Last Modified: 24 Sep 2022 07:04
URI: https://ueaeprints.uea.ac.uk/id/eprint/87428
DOI: 10.1111/myc.13336

Actions (login required)

View Item View Item